Xponance Inc. Reduces Johnson & Johnson Holdings

Institutional investor cuts stake in pharmaceutical giant by 4% in Q3

Published on Feb. 27, 2026

Got story updates? Submit your updates here. ›

Xponance Inc., an institutional investor, reduced its holdings in Johnson & Johnson (NYSE:JNJ) by 4% during the third quarter, according to a recent SEC filing. The firm now owns 390,745 shares of the company's stock, valued at $72.45 million.

Why it matters

Johnson & Johnson is a major pharmaceutical and consumer healthcare company, and changes in institutional ownership can provide insights into market sentiment around the stock. Xponance's reduction in its JNJ position, even as the stock price rose, may signal some caution among investors about the company's outlook.

The details

Xponance Inc. sold 16,144 shares of Johnson & Johnson stock during the third quarter, reducing its total position by 4%. The firm now holds 390,745 shares, making JNJ its 22nd largest holding and accounting for 0.6% of its overall portfolio.

  • Xponance Inc. made the portfolio changes in the third quarter of 2026.

The players

Xponance Inc.

An institutional investment firm that manages assets for clients.

Johnson & Johnson

A multinational pharmaceutical and consumer goods company headquartered in New Brunswick, New Jersey.

Got photos? Submit your photos here. ›

The takeaway

Xponance's reduction in its Johnson & Johnson holdings, despite the stock's rising price, suggests some caution among institutional investors about the company's outlook, even as it remains a significant position in the firm's portfolio.